Cisbio Bioassays Establishes Sales Operations in Asia

The company is a developer of homogeneous time-resolved fluorescence (HTRF) technology and services for assay development and drug screening. HTRF is a highly sensitive, robust technology for the detection of molecular interactions.

Sales of Cisbio Bioassays' HTRF-based tools, which include IP-One, cAMP, and Cellul'erk assays, and the Tag-lite cell surface receptor platform, will be handled in China by IBA China, IBA group's Beijing- based subsidiary. Sales in South Korea will be handled by JCBio Co., Ltd., a Seoul-based distributor specialized in products used by pharmaceutical and biotechnology laboratories. The local sales teams will enable the company to offer its G-protein coupled receptors (GPCR) and kinase technology platforms, biomarker assays, and related services to customers in pharmaceutical and biotechnology markets.

In addition to its HTRF- based tools, the company offers a range of services, including custom labeling of specific assay components, custom assay design and development, and HTRF technology training. The company is a global developer of products and technologies used for in vitro diagnostics (IVD) and assay development for drug screening procedures. In addition, Cisbio Bioassays produces a selection of biologic reagents and methods used by pharmaceutical and biotechnology companies, as well as contract research organizations (CROs). Cisbio Bioassays won the Frost & Sullivan (Palo Alto, CA, USA) 2009 North American Technological Innovation of the Year Award.

IBA is primarily active in the medical industry. It develops and markets equipment and radiopharmaceuticals for cancer diagnosis and treatment. In addition, it uses the scientific expertise thus gained to provide electron accelerators for industrial sterilization and ionization.

Related Links:
Cisbio Bioassays
IBA group
IBA China
JCBio